Stockreport

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-brea [Read more]